Routes ofadministration Oral Legal status Investigational CAS Number 905854-02-6 Molar mass 369.42 g/mol ChEMBL ID 2103882 | ATC code none Synonyms ARQ197; ARQ-197 PubChem CID 11494412 Pubchem 11494412 ChemSpider ID 9669218 | |
 | ||
Dr finn on tivantinib and regorafenib for the treatment of liver cancer
Tivantinib (ARQ197; by Arqule, Inc.) is an experimental anti-cancer drug. It is a bisindolylmaleimide that binds to the dephosphorylated MET kinase in vitro. (MET is a growth factor receptor.) Tivantinib is being tested clinically as a highly selective MET inhibitor. However, the mechanism of action of tivantinib is still unclear.
Contents
- Dr finn on tivantinib and regorafenib for the treatment of liver cancer
- Dr lorenza rimassa on tivantinib for egfr inhibitor resistant mcrc
- References
Tivantinib displays cytotoxic activity via molecular mechanisms that are independent from its ability to bind MET.
Possible applications include non-small-cell lung carcinoma, hepatocellular carcinoma, and oesophageal cancer.
In 2017 it failed a phase III clinical trial for advanced hepatocellular carcinoma (HCC).
Dr lorenza rimassa on tivantinib for egfr inhibitor resistant mcrc
References
Tivantinib Wikipedia(Text) CC BY-SA